A 2026 BD opportunity scan of Dexcel Pharma Technologies Ltd, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Aucta Pharmaceuticals, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Bened Biomedical Co., Ltd., covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Excelsior BioPharma Inc., covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of AVIR Pharma Inc., covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Acrotech Biopharma, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Boryung Biopharma, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Dr. Falk Pharma GmbH, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Fuso Pharmaceutical Industries, Ltd., covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Etern Therapeutics, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of CKD Pharmaceutical Corp., covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Cosette Pharmaceuticals, Inc., covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.